AQST Aquestive Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AQST

Price (delayed)

$3.83

Market cap

$348.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$368.61M

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
AQST's equity has surged by 67% year-on-year and by 66% since the previous quarter
The EPS has grown by 35% year-on-year
The debt has grown by 2.3% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://aquestive.com
Peers: OPK OPTN

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
91.04M
Market cap
$348.68M
Enterprise value
$368.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.16
Earnings
Revenue
$51.5M
EBIT
-$18.35M
EBITDA
-$17.12M
Free cash flow
-$26.6M
Per share
EPS
-$0.43
Free cash flow per share
-$0.36
Book value per share
-$0.5
Revenue per share
$0.7
TBVPS
$1.74
Balance sheet
Total assets
$129.52M
Total liabilities
$165.82M
Debt
$115.14M
Equity
-$36.3M
Working capital
$95.32M
Liquidity
Debt to equity
-3.17
Current ratio
6.28
Quick ratio
5.73
Net debt/EBITDA
-1.16
Margins
EBITDA margin
-33.2%
Gross margin
60.2%
Net margin
-55.9%
Operating margin
-37.8%
Efficiency
Return on assets
-37.9%
Return on equity
N/A
Return on invested capital
-15.3%
Return on capital employed
-16.5%
Return on sales
-35.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
11.01%
1 week
19.69%
1 month
58.26%
1 year
125.29%
YTD
89.6%
QTD
47.31%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$51.5M
Gross profit
$31.02M
Operating income
-$19.45M
Net income
-$28.77M
Gross margin
60.2%
Net margin
-55.9%
Aquestive Therapeutics's operating margin has surged by 52% YoY but it has decreased by 26% QoQ
The operating income has increased by 47% YoY but it has decreased by 29% from the previous quarter
The net margin has grown by 21% YoY
The company's gross profit rose by 16% YoY and by 4.3% QoQ

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.16
The EPS has grown by 35% year-on-year
AQST's equity has surged by 67% year-on-year and by 66% since the previous quarter
AQST's P/S is 97% above its 5-year quarterly average of 2.5 and 54% above its last 4 quarters average of 3.2
Aquestive Therapeutics's revenue has increased by 11% YoY

Efficiency

How efficient is Aquestive Therapeutics business performance
AQST's ROA has dropped by 183% since the previous quarter but it is up by 35% year-on-year
The return on sales has grown by 27% year-on-year
The company's return on invested capital rose by 22% YoY

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 22% lower than its total liabilities
The current ratio has surged by 180% since the previous quarter
The company's total assets has surged by 126% QoQ and by 111% YoY
AQST's debt to equity has dropped by 199% since the previous quarter
AQST's equity has surged by 67% year-on-year and by 66% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.